Narayana Hrudayalaya Performance
- Today's Low
- ₹1,911
- Today's High
- ₹1,983
- 52 Week Low
- ₹1,589
- 52 Week High
- ₹2,370
- Open Price₹1,945
- Previous Close₹1,969
- Volume268,635
- 50 DMA₹1,844.51
- 100 DMA₹1,821.59
- 200 DMA₹1,794.49
Narayana Hrudayalaya Chart
Investment Returns
- Over 1 Month + 3.51%
- Over 3 Month + 9.46%
- Over 6 Month + 0.23%
- Over 1 Year + 9.75%
Smart Investing Starts Here Start SIP with Narayana Hrudayalaya for Steady Growth!
Narayana Hrudayalaya Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 48.7
- PEG Ratio
- 24.9
- Market Cap Cr
- 39,266
- P/B Ratio
- 9.4
- Average True Range
- 60.35
- EPS
- 41.68
- Dividend Yield
- 0.2
- MACD Signal
- 37.72
- RSI
- 54.67
- MFI
- 64.13
Latest Stock News Updates
States can choose from four funding models, including sharing land acquisition costs, to support ring roads, bypasses and elevated corridors around cities
- Business Standard
- 6 days 2 hours ago
Healthcare Facilities company Narayana Hrudayalaya announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from operations: For Q4FY26, revenue stood at Rs 25,938.06 million, reflecting a strong YoY growth of 75.80% from Rs 14,754.38 million in Q4FY25, and a QoQ increase of 20.58% from Rs 21,511.70 million in Q3FY26. Annual revenue for FY26 was Rs 78,960.35 million, marking a 44.01% YoY growth compared to Rs 54,829.77 million in FY25. Total income: Total income for Q4FY26 was Rs 26,230.35 million, up 74.60% YoY against Rs 15,022.80 million in Q4FY25, and an increase of 20.63% QoQ from Rs 21,743.76 million in Q3FY26. The total income for FY26 reached Rs 79,962.54 million, up 43.43% YoY from Rs 55,750.12 million in FY25. EBITDA: Q4FY26 EBITDA grew by 40.21% YoY to Rs 5,392.12 million from Rs 3,845.63 million in Q4FY25, and increased 38.10% QoQ from Rs 3,904.43 million in Q3FY26. Annual EBITDA for FY26 stood at Rs 17,168.91 million, up 25.46% YoY from Rs 13,684.22 million in FY25. Profit after tax (Net profit): Net profit for Q4FY26 was Rs 2,239.92 million, showing a YoY growth of 13.54% from Rs 1,972.86 million in Q4FY25, and a 76.67% QoQ jump from Rs 1,267.85 million in Q3FY26. For FY26, the net profit stood at Rs 8,059.79 million, representing a slight YoY increase of 1.94% compared to Rs 7,906.31 million in FY25. Standalone Financial Highlights: Revenue from operations: Q4FY26 revenue was Rs 10,440.50 million, registering a YoY increase of 13.60% from Rs 9,190.27 million in Q4FY25, and a QoQ growth of 7.77% from Rs 9,687.81 million in Q3FY26. Annual revenue for FY26 grew by 10.72% YoY to Rs 39,751.41 million from Rs 35,901.22 million in FY25. Total income: Total income for Q4FY26 stood at Rs 11,711.09 million, up 14.18% YoY against Rs 10,256.91 million in Q4FY25, and up 18.94% QoQ from Rs 9,846.32 million in Q3FY26. For FY26, total income was Rs 41,515.75 million, up 11.23% YoY from Rs 37,322.85 million in FY25. EBITDA: Q4FY26 EBITDA surged 25.23% YoY to Rs 3,536.74 million from Rs 2,824.31 million in Q4FY25, and increased 60.31% QoQ from Rs 2,206.15 million in Q3FY26. Annual EBITDA for FY26 stood at Rs 10,158.82 million, up 24.85% YoY from Rs 8,137.02 million in FY25. Profit after tax (Net profit): Net profit for Q4FY26 stood at Rs 2,021.25 million, reflecting a YoY growth of 26.35% from Rs 1,599.76 million in Q4FY25, and an increase of 166.88% QoQ from Rs 757.37 million in Q3FY26. Annual net profit for FY26 stood at Rs 5,031.13 million, showing a 16.69% YoY growth from Rs 4,311.42 million in FY25. Business Highlights: Segment-wise Performance: Medical and Healthcare related services: For Q4FY26, the segment's revenue from operations was Rs 25,019.74 million, reflecting an increase of 66.80% YoY and 20.88% QoQ. Full-year FY26 revenue reached Rs 76,886.87 million, up 37.09% YoY from Rs 56,085.18 million in FY25. Others: Q4FY26 revenue from operations was Rs 1,336.74 million, marking a multi-fold YoY growth of 621.12% and a 9.90% QoQ growth. Annual FY26 revenue for this segment surged by 1132.42% YoY to Rs 3,856.50 million. Corporate and Strategic Updates: Dividend: The Board of Directors recommended a final dividend of Rs 4.50/- per share for FY26. Fund Raising: The Board resolved to seek enabling approval from shareholders for issuing Debt Securities, including Non-Convertible Debentures (NCDs), for an amount not exceeding Rs 1,500 crore in a financial year in one or more series/tranches on a private placement basis. Major Acquisition: Narayana Hrudayalaya UK Ltd, a wholly-owned subsidiary of Health City Cayman Islands Limited, successfully acquired 100% equity shares in Practice Plus Group Hospitals Limited, UK for a total consideration of GBP 188.78 million (Rs 22,009.69 million). The transaction was completed on November 6, 2025. Merger and Restructuring: The Board approved the Scheme of Arrangement for the merger of Meridian Medical Research & Hospital Ltd. (MMRHL) into the Company, with an appointed date of April 1, 2024. Similarly, a scheme to demerge the clinical services of NH Integrated Care Private Limited (NHIC) into the Company was also approved. Business Transition: The business operations and control of Shri Mata Vaishno Devi Narayana Superspeciality Hospital were transferred to Shri Mata Vaishno Devi Charitable Society (SMVDCS) effective April 1, 2026. The Company’s subsidiary will now continue to provide management and consultancy support. New Incorporation: The Company incorporated a wholly-owned subsidiary, Narayana Healthcare North Private Limited (NHNPL), on January 16, 2026. Emmanuel Rupert, Managing Director & Group CEO, Narayana Hrudayalaya, said: “FY26 marked an important milestone in the company’s journey with the successful acquisition of the hospital business of Practice Plus Group in November 2025. By the close of the financial year, the acquired entity had completed close to two quarters within NH, and integration is progressing in line with management expectations. We are pleased to report the highest-ever revenue at the Group level in the fourth quarter with all our geographies performing well. The India business saw positive outcomes from its domestic focus, transformation initiatives, high-value procedures, and efficient usage of technology, delivering the highest-ever revenue and profitability for the quarter. Narayana One Health continues to strengthen the integrated healthcare delivery model, and the expanding clinic and insurance network has enhanced patient outreach, contributing positively to the overall India business. Our Cayman business delivered another year of robust performance and benefited from the addition of Health City Camana Bay and sustained demand across specialties. One Health Cayman, our integrated health insurance platform, continues to further strengthen patient access and affordability within the ecosystem. We thank the investor community for their faith in us and remain confident of delivering on expectations for the upcoming year.” Result PDF
- Trendlyne
- 2 weeks ago
For the January to March quarter of FY26, Narayana Hrudayalaya delivered record revenue and profit growth, driven by strong operational performance across geographies.
- Business Standard
- 2 weeks ago
Narayana Hrudayalaya Financials
Narayana Hrudayalaya Technicals
EMA & SMA
- Bearish Moving Average 5
- Bullish Moving Average 11
- 20 Day
- ₹1,899.11
- 50 Day
- ₹1,844.51
- 100 Day
- ₹1,821.59
- 200 Day
- ₹1,794.49
Resistance and Support
- R3 2,037.77
- R2 2,010.33
- R1 1,965.87
- S1 1,893.97
- S2 1,866.53
- S3 1,822.07
Narayana Hrudayalaya Corporate Actions - Bonus, Splits, Dividends
About Narayana Hrudayalaya
- NSE Symbol
- NH
- BSE Symbol
- 539551
- Managing Director & Group CEO
- Dr. Emmanuel Rupert
- ISIN
- INE410P01011
Similar Stocks to Narayana Hrudayalaya
Popular Stocks
Narayana Hrudayalaya FAQs
Narayana Hrudayalaya share price is ₹1,921 As on 09 June, 2026 | 00:24
The Market Cap of Narayana Hrudayalaya is ₹39265.9 Cr As on 09 June, 2026 | 00:24
The P/E ratio of Narayana Hrudayalaya is 48.7 As on 09 June, 2026 | 00:24
The PB ratio of Narayana Hrudayalaya is 9.4 As on 09 June, 2026 | 00:24
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.